156 related articles for article (PubMed ID: 21898387)
1. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study.
Jézéquel P; Campion L; Spyratos F; Loussouarn D; Campone M; Guérin-Charbonnel C; Joalland MP; André J; Descotes F; Grenot C; Roy P; Carlioz A; Martin PM; Chassevent A; Jourdan ML; Ricolleau G
Int J Cancer; 2012 Jul; 131(2):426-37. PubMed ID: 21898387
[TBL] [Abstract][Full Text] [Related]
2. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer.
Gwak JM; Jang MH; Kim DI; Seo AN; Park SY
PLoS One; 2015; 10(4):e0125728. PubMed ID: 25884955
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study.
Descotes F; Jézéquel P; Spyratos F; Campion L; Grenot C; Lerebours F; Campone M; Guérin-Charbonnel C; Lanoë D; Adams M; André J; Carlioz A; Martin PM; Chassevent A; Jourdan ML; Guette C; Zanella-Cleon I; Ricolleau G
Int J Oncol; 2012 Jul; 41(1):92-104. PubMed ID: 22552268
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer.
Tang X
Cancer Lett; 2013 May; 332(1):3-10. PubMed ID: 23348699
[TBL] [Abstract][Full Text] [Related]
6. SELDI-TOF-MS proteomics of breast cancer.
Clarke CH; Buckley JA; Fung ET
Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
[TBL] [Abstract][Full Text] [Related]
7. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
8. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
Boccardo F; Rubagotti A; Nuzzo PV; Argellati F; Savarino G; Romano P; Damonte G; Rocco M; Profumo A
Int J Cancer; 2015 Nov; 137(10):2394-402. PubMed ID: 25994113
[TBL] [Abstract][Full Text] [Related]
9. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value.
Rosager AM; Sørensen MD; Dahlrot RH; Hansen S; Schonberg DL; Rich JN; Lathia JD; Kristensen BW
PLoS One; 2017; 12(8):e0182954. PubMed ID: 28837569
[TBL] [Abstract][Full Text] [Related]
10. MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin.
Bønnelykke-Behrndtz ML; Steiniche T; Damsgaard TE; Georgsen JB; Danielsen A; Bastholt L; Møller HJ; Nørgaard PH; Schmidt H
Melanoma Res; 2015 Apr; 25(2):113-8. PubMed ID: 25602697
[TBL] [Abstract][Full Text] [Related]
11. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
12. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
Zhang GQ; Du J; Pang D
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of archival breast cancer serum.
Zeidan BA; Cutress RI; Murray N; Coulton GR; Hastie C; Packham G; Townsend PA
Cancer Genomics Proteomics; 2009; 6(3):141-7. PubMed ID: 19487543
[TBL] [Abstract][Full Text] [Related]
14. [Proteomics and breast cancer].
Mathelin C; Tomasetto C; Cromer A; Rio MC
Gynecol Obstet Fertil; 2006 Dec; 34(12):1161-9. PubMed ID: 17123853
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
16. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Gonçalves A; Bertucci F; Birnbaum D; Borg JP
Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
[TBL] [Abstract][Full Text] [Related]
17. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
18. Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.
Lei L; Wang XJ; Zheng ZG; Huang J; Cao WM; Chen ZH; Shao XY; Cai JF; Ye WW; Lu HY
Anat Rec (Hoboken); 2011 Jun; 294(6):941-4. PubMed ID: 21548109
[TBL] [Abstract][Full Text] [Related]
19. [Surface enhanced laser desorption/ionization (SELDI): proteomics technology and its application in oncology].
Espejel F; Roa JC
Med Clin (Barc); 2008 Sep; 131(8):312-7. PubMed ID: 18803927
[TBL] [Abstract][Full Text] [Related]
20. SELDI-TOF serum proteomics and breast cancer: which perspective?
Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
